| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,652 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
| Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Klaskin Christine M |
VP, Finance |
• – – |
2009-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,336 |
21,601 |
|
- |
|
| Hatsopoulos John |
Director |
– • – |
2008-09-04 |
4 |
B |
$1.72 |
$5,160 |
D/D |
3,000 |
45,000 |
2.39 |
- |
|
| Hatsopoulos John |
Director |
– • – |
2008-09-03 |
4 |
B |
$1.71 |
$11,970 |
D/D |
7,000 |
42,000 |
2.39 |
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2008-07-10 |
4 |
D |
$1.76 |
$35,719 |
D/D |
(20,295) |
917,159 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2008-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
60,044 |
937,454 |
|
- |
|
| Wentworth Kerry |
VP Reg Aff and Clinical Ops |
• – – |
2008-07-10 |
4 |
D |
$1.76 |
$11,181 |
D/D |
(6,353) |
24,672 |
|
- |
|
| Wentworth Kerry |
VP Reg Aff and Clinical Ops |
• – – |
2008-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
24,018 |
31,025 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2008-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
26,201 |
55,890 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2008-07-10 |
4 |
D |
$1.76 |
$9,152 |
D/D |
(5,200) |
21,282 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2008-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
16,376 |
26,482 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2008-07-10 |
4 |
D |
$1.76 |
$9,692 |
D/D |
(5,507) |
17,265 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2008-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
15,148 |
22,772 |
|
- |
|
| Valentine Karen |
VP and General CounselOfficer |
• – – |
2008-06-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,106 |
|
- |
|
| Margaret Eisen |
Director |
– • – |
2008-05-16 |
4 |
B |
$2.36 |
$35,348 |
D/D |
15,000 |
20,000 |
2.39 |
- |
|
| Debbane Raymond |
10% Owner |
– – • |
2008-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,533,333 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2008-03-24 |
4 |
A |
$2.28 |
$971 |
D/D |
426 |
5,643 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2008-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
6,069 |
|
- |
|
| Wentworth Kerry |
VP Reg Affairs & Clinical Ops |
• – – |
2008-03-24 |
4 |
D |
$2.28 |
$1,243 |
D/D |
(545) |
7,007 |
|
- |
|
| Wentworth Kerry |
VP Reg Affairs & Clinical Ops |
• – – |
2008-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,667 |
7,552 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2008-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,667 |
29,689 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2008-01-09 |
4 |
B |
$3.00 |
$3,500,001 |
I/I |
1,166,667 |
12,655,941 |
1.99 |
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2008-01-09 |
4 |
B |
$3.00 |
$1,626,150 |
D/D |
542,050 |
877,410 |
2.74 |
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2008-01-07 |
4 |
A |
$2.15 |
$3,967 |
D/D |
1,845 |
5,069 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2008-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
4,336 |
6,914 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2008-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
68,750 |
335,360 |
|
- |
|
536 Records found
|
|
Page 20 of 22 |
|
|
